First malaria treatment for babies approved for use

First malaria treatment suitable for babies and very young children approved for use, filling a gap in pediatric medicine. The drug, developed by Novartis, is set to be introduced in African countries to combat the high rates of malaria deaths among children under five. With almost all malaria-related deaths occurring in Africa in 2023, this new treatment is a crucial step in saving the lives of the smallest and most vulnerable babies at risk of the disease.